Stifel, Neumora
The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been fil ...
NEW YORK, NY / ACCESS Newswire / March 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Research analysts at HC Wainwright increased their Q2 2025 earnings per share (EPS) estimates for shares of Neumora Therapeutics in a research report issued to clients and investors on Tuesday, March ...
Clinical Trials Arena on MSN2d
J&J drops Phase III MDD programme due to lack of efficacyJ&J said it plans to “explore future development opportunities for aticaprant in other areas of high unmet need”. A statement ...
Robert Lenz is leaving the brain drug developer to “pursue other interests.” Elsewhere, Atara is cutting half of its staff ...
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by investment ...
Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...
Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...
KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
H.C. Wainwright lowered the firm’s price target on Neumora Therapeutics (NMRA) to $18 from $30 and keeps a Buy rating on the shares. The firm ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback